Docetaxel Injection

Effects and efficacy:
For the treatment of locally advanced or metastatic breast cancer. Combined with trastuzumab for the treatment of metastatic breast cancer that has not received chemotherapy for metastatic breast cancer and overexpresses the human epidermal growth factor receptor-2 (HER2) gene. Combined with doxorubicin and cyclophosphamide for postoperative adjuvant chemotherapy for patients with lymph node-positive breast cancer. For the treatment of locally advanced or metastatic non-small cell lung cancer, even after failure of cisplatin-based chemotherapy. Combined with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Combined with cisplatin and fluorouracil for the treatment of advanced gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma) that has not received chemotherapy before.
Usage and dosage:
Docetaxel can only be used for intravenous infusion, and the recommended dose is 75mg/m2 infused for one hour every three weeks. Please use it according to your doctor’s advice. For breast cancer In adjuvant chemotherapy for node-positive breast cancer that is operable, the recommended dose is: 1 hour after doxorubicin (50 mg/m) and cyclophosphamide (500 mg/m), docetaxel 75 mg/m is given once every 3 weeks for 6 cycles (see [Dose Adjustment During Treatment]). Please follow your doctor’s advice for details. When treating patients with locally advanced or metastatic breast cancer, the recommended dose of docetaxel alone is 100 mg/m. When used as a first-line drug, docetaxel (75 mg/m) is combined with doxorubicin (50 mg/m). When used in combination with trastuzumab, the recommended dose of docetaxel is 100 mg/m once every three weeks, and trastuzumab is given once a week. In a key clinical study, the first intravenous administration of docetaxel should be one day after the first dose of trastuzumab. If the patient tolerates the previous dose of trastuzumab well, subsequent docetaxel administration should be administered immediately after the intravenous infusion of trastuzumab. When used for the treatment of non-small cell lung cancer, the recommended dose for previously untreated patients is docetaxel 75 mg/m, and cisplatin 75 mg/m is immediately given intravenously for 30-60 minutes. For patients who have failed previous platinum-containing drug treatment, the recommended dose of docetaxel is 75 mg/m monotherapy. When used for the treatment of prostate cancer, prednisone or prednisolone is given at the same time. The recommended pre-chemotherapy dose and regimen are: patients take oral dexamethasone 8 mg 12 hours, 3 hours and 1 hour before receiving docetaxel treatment. Prophylactic use of granulocyte colony-stimulating factor (G-CSF) to reduce the risk of drug hematotoxicity. Please follow the doctor’s advice for details. The recommended dose is docetaxel 75 mg/m, a course of treatment every 3 weeks, and continuous oral prednisone or prednisolone twice a day, 5 mg each time. Adjust the dose during treatment. Docetaxel cannot be used in patients with neutrophil counts below 1500/mm3. During medication, if the patient develops febrile neutropenia, the neutrophil count is less than 500/mm3 for more than one week, severe or cumulative skin reactions or severe peripheral neurologic symptoms, the dose of docetaxel should be reduced as appropriate. For patients receiving adjuvant chemotherapy for breast cancer who develop concurrent neutropenia (including prolonged neutropenia, febrile neutropenia or infection), it is recommended to use G-CSF prophylactically (such as day 4 to day 11) in all subsequent medication cycles. If the patient continues to experience the above reactions, G-CSF should be used continuously and the dose of docetaxel should be reduced to 60mg/m2. If G-CSF is not used, the dose of docetaxel should be reduced from 75 to 60mg/m2. Patients who develop grade 3 or 4 stomatitis should have their dose reduced to 60mg/m2. Please consult your doctor for details. For patients who started with docetaxel 75 mg/m2 combined with cisplatin and had a platelet nadir of <25,000/mm3, or had febrile neutropenia, or had severe non-hematological toxicity in the previous course of treatment, the docetaxel dose for the next course of treatment should be reduced to 65 mg/m2. Based on the pharmacokinetic data of 100 mg/m2 docetaxel monotherapy, the recommended dose of docetaxel is 75 mg/m2 for patients with ALT and/or AST exceeding 1.5 times the upper limit of normal and alkaline phosphatase exceeding 2.5 times the upper limit of normal. For patients with serum bilirubin exceeding the upper limit of normal and/or ALT and AST exceeding 3.5 times the upper limit of normal and alkaline phosphatase exceeding 6 times the upper limit of normal, it should not be used unless there is a strict indication for use, and there is no recommendation for dose reduction. Note: To reduce the occurrence of fluid retention and the severity of allergic reactions, all patients must take pre-medication (only oral glucocorticoids, such as dexamethasone) before receiving docetaxel treatment, unless there are contraindications. The pre-medication should be taken one day before docetaxel infusion, 16 mg per day (such as 8 mg twice a day) for 3 days. Only doctors can modify the treatment plan.
Drug contraindications:
Allergy to this product is prohibited. It is prohibited during pregnancy. It is prohibited for liver damage. It should be used with caution during lactation.
Related dosage forms:
Injection